Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.

Author: ChangJianhua, FanYun, NianWeiqi, QinMengmeng, ShenZhenwei, ShiHuaqiu, SunMeili, SunYuping, WangHuijie, WangKe, WangXiangcai, WuGang, WuYi-Long, YangJason, YaoSheng, ZhaoJun, ZhengXiangqian, ZhouQing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pralsetinib, a RET inhibitor, demonstrated robust and durable clinical activity with a well-tolerated safety profile in Chinese patients with RET fusion-positive non-small cell lung cancer (NSCLC). The objective response rate was 66.7% in pretreated patients and 83.3% in treatment-naive patients. Median progression-free survival was 11.7 months in pretreated patients and 12.7 months in treatment-naive patients. The most common grade 3/4 treatment-related adverse events were anemia (35.3%) and decreased neutrophil count (33.8%).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Pralsetinib is a potent, selective RET inhibitor targeting oncogenic RET alterations. As part of the global, phase 1/2 ARROW trial (NCT03037385), the efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) were evaluated...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.34897

データ提供：米国国立医学図書館（NLM）

Pralsetinib: A New Oasis for RET Fusion-Positive Lung Cancer

RET fusion-positive non-small cell lung cancer (NSCLC) is a formidable desert storm, leaving patients with limited treatment options. This research explores the efficacy and safety of pralsetinib, a potent RET inhibitor, as a potential oasis for individuals with this aggressive form of lung cancer. The study, part of the global ARROW trial, evaluated pralsetinib in Chinese patients with advanced RET fusion-positive NSCLC, both those who had received prior chemotherapy and those who were treatment-naïve. The researchers monitored for response rates, progression-free survival, and safety outcomes.

Finding a Path to Relief

The study demonstrated robust and durable clinical activity with pralsetinib, showing significant response rates and prolonged progression-free survival in both treatment groups. The most common side effects were mild and manageable, suggesting that pralsetinib offers a promising treatment option for RET fusion-positive NSCLC. These findings provide hope for individuals battling this aggressive form of cancer, offering a new path to relief and improved quality of life.

A Glimmer of Hope in the Lung Cancer Desert

This research offers a beacon of hope for individuals with RET fusion-positive NSCLC, providing a new weapon in the fight against this aggressive disease. The study's findings highlight the importance of precision medicine, tailoring treatments to the specific genetic mutations driving the disease. This research underscores the need for continued research into innovative therapies for lung cancer, offering a potential oasis for those seeking to overcome this formidable desert storm.

Dr.Camel's Conclusion

RET fusion-positive lung cancer can feel like a relentless desert storm, leaving patients with limited options. This research explores pralsetinib, a targeted therapy, as a potential oasis of relief. The findings show promising results in terms of response rates and safety, offering hope for individuals battling this aggressive form of cancer.

Date :
  1. Date Completed 2023-09-22
  2. Date Revised 2023-09-26
Further Info :

Pubmed ID

37282666

DOI: Digital Object Identifier

10.1002/cncr.34897

Related Literature

Article Analysis
・Effects of pralsetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.